Search Results - Domokos, G.

Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years by Pennell, D., Porter, J.B., Cappellini, M.D., Chan, L.L., El-Beshlawy, A., Aydinok, Y., Ibrahim, H., Li, Chi-Kong, Viprakasit, V., Elalfy, M.S., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A.

Get full text

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia by Pennell, D.J., Porter, J.B., Cappellini, M.D., El-Beshlawy, A., Chan, L.L., Aydinok, Y., Elalfy, M.S., Sutcharitchan, P., Li, C.K., Ibrahim, H., Viprakasit, V., Kattamis, A., Smith, G., Habr, D., Domokos, G., Roubert, B., Taher, A.

Get full text

Tailoring iron chelation by iron intake and serum ferritin: The prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias by Cappellini, M.D., Porter, J., El-Beshlawy, A., Li, C.K., Seymour, J.F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J.W., Chan, L.L., Lin, K.H., Rose, C., Taher, A., Thein, S.L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A., Investigators, EPIC Study

Get full text